аЯрЁБс>ўџ 24ўџџџ1џџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџьЅС'` №П]bjbjыШыШ 4‰Ђ‰Ђ] џџџџџџЄ№№№№№№№Ь Ь Ь Ь и ]ј ј ј ј ј ј ј ј моооооо$mhе№ј ј ј ј ј №№ј ј ŒŒŒј v№ј №ј мŒј мŒŒ№№Œј ь •ь T8ЪЬ n Œм-0]Œяx яŒя№ŒPј ј Œј ј ј ј ј ‚ ј ј ј ]ј ј ј ј фшфш№№№№№№џџџџ DRUG DEVELOPMENT AND DRUG SAFETY (MSc/PgDip with a view to transfer to MSc/PgDip/PgCert) 57B2DSB1/61B2DSB1/61B2DSVX/62B2DSVZ Qualifications for entry: A degree or equivalent qualification, at the prescribed standard in Medicine, Pharmacology, Pharmacy or a relevant Science subject (e.g. Biochemistry, Biomedical Sciences, Biology). Duration: 12 months full-time or 24 months part-time (MSc); 9 months full-time or 18 months part-time (PgDip). Aim: To equip students for careers/research in the development and safety assessment of new and current drugs. To achieve this, the programme will provide a multi-disciplinary approach to the study of drug discovery and development; mechanisms of drug-induced toxicity; preclinical and clinical trials; regulatory affairs. Content: The programme of taught courses will comprise lectures, tutorials, practical classes and small group demonstrations in laboratories and clinical departments. The curriculum includes biochemical and molecular aspects of drug action; drug transport, metabolism and excretion, with an emphasis on humans; molecular biology and bioanalytical methods e.g. mass spectroscopy; mechanisms of drug-induced toxicity, reproductive toxicology, immunotoxicology and neurotoxicology; pharmacokinetics; toxicokinetics; statistics; computing studies; industrial aspects of drug development; therapeutics; therapeutic drug monitoring; the design and conduct of volunteer and clinical trials; assessment of drug safety. Candidates shall be required to attend the following designated programme of courses: First Half-Session GS 50M1 Generic Skills (0 credit points) MB 5009 Molecular Biology Basics (10 credit points) MT 5010 Basic Skills – Induction (0 credit points) MT 5011 Molecular Pharmacology, immunology and Oncology (15 credit points) MT 5012 Human Drug Metabolism and Molecular Toxicology (20 credit points) MT 5013 Therapeutics for Scientists (5 credit points) PU 5005 Applied Statistics (10 credit points) SK 5003 Information Skills (0 credit points) Second Half-Session MT 5501 Pharmacovigilance (5 credit points) MT 5502 Drug Development to Evidence Based Medicine (20 credit points) MT 5508 Clinical Pharmacology (5 credit points) MT 5509 Pharmacokinetics and Toxicokinetics (10 credit points) MT 5510 Introduction to Research Methods (10 credit points) Final Stage MT 5900 Research Project (70 credit points) Assessment: By practical work, by written essays and by oral presentations, or by a combination of these, as prescribed for each course. The thesis/dissertation will be assessed and there may be an oral examination on completion of the programme. Yb}~˜Q Z Т Ц   );є(3bmZ\]ішншівівівівіЧіЧіЧівіКЖhVhœyНhбOJQJ^Jhб>*OJQJ^Jhб6OJQJ^Jhб5OJQJ^Jh§Шhб5OJQJ^JhбOJQJ^JY~P Q С Т   б в ()<=fšЭb˜Цѓєѓъѓххххххххххххмммммммммм Ц„gdбgdб ЦD%gdб  Ц 0D%Тgdб]§ 5|Ќы'(45ab[\]іііііііііііііє Ц„gdб21h:pektА‚. АЦA!А№"А№#№$№%ААТАТ Ф†œJ`ёџJ бNormal$a$CJOJQJ_HmH sH tH >`> б Heading 3$d8џ@&5DA@ђџЁD Default Paragraph FontVi@ѓџГV  Table Normal :V і4ж4ж laі (k@єџС(No List ] џџџџY~PQСТбв()<=fšЭb˜Цѓє 5|Ќы' ( 4 5 a b [ \ _ (@0€|с˜@0€Yу(@0€|с˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зу˜@0€зуhЫ00€Y~PQСТбв()<=fšЭb˜Цѓє 5|Ќы' ( 4 5 a b [ \ _ *@0€€€š@0€€*@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€š@0€€ 00\ ] ] ] &+KWЙОWdУгичћ "Щз_ _ _ _ х AбП #6, DektVd„ƒ(‹4mЅф фсlєгјџ@€\ \ † \ \ ] `@џџUnknownџџџџџџџџџџџџG‡z €џTimes New Roman5€Symbol3& ‡z €џArialY CG TimesTimes New Roman"qˆ№аh"“йІ"“йІ‹в‹в№№№xД‚‚r4X X  2ƒq№мHP)№џ?фџџџџџџџџџџџџџџџџџџџџџб2џџXDRUG DEVELOPMENT AND DRUG SAFETY (MSc/PgDip with a view to transfer to MSc/PgDip/PgCert)Lorraine GerrardLorraine Gerrardўџр…ŸђљOhЋ‘+'Гй0и˜ќ$0<L ht ”   ЌИРШаф\DRUG DEVELOPMENT AND DRUG SAFETY (MSc/PgDip with a view to transfer to MSc/PgDip/PgCert)Lorraine GerrardNormalLorraine Gerrard1Microsoft Office Word@@nъS8Ъ@nъS8Ъ‹вўџеЭеœ.“—+,љЎ0T hp˜ Ј АИРШ а 5ф51cgX ' YDRUG DEVELOPMENT AND DRUG SAFETY (MSc/PgDip with a view to transfer to MSc/PgDip/PgCert) Title ўџџџўџџџ ўџџџ"#$%&'(ўџџџ*+,-./0ўџџџ§џџџ3ўџџџўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџ РFр(ё T8Ъ5€Data џџџџџџџџџџџџ1TableџџџџяWordDocumentџџџџ4SummaryInformation(џџџџџџџџџџџџ!DocumentSummaryInformation8џџџџџџџџ)CompObjџџџџџџџџџџџџqџџџџџџџџџџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџ џџџџ РFMicrosoft Office Word Document MSWordDocWord.Document.8є9Вq